Amgen is trading 3.18% up now at $405.67 after favorable developments surrounding tarlatamab (Imdelltra), including a statistically significant Phase 3 overall-survival improvement when combined with AstraZeneca’s Imfinzi.

  • An FDA label update shortened monitoring for the first two doses, improving treatment convenience.
  • Company-specific catalysts are outweighing the broader market’s modest gains on September 22, 2026.